RAREUltragenyx Pharmaceutical Inc.同业对比
Ultragenyx Pharmaceutical Inc. 与SPDR S&P Biotech ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:XBI 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RARE本股 | $1.7B#15 | — | — | 2.5x#1 | 20.2%#5 | -1.1%#7 | -79.5%#2 | — | — | — | -49.7%#6 | — |
| MRNA | $92.5B#1 | — | 13.7x#9 | 47.6x#4 | -39.9%#7 | 20.8%#5 | -158.1%#4 | -41.7%#11 | -54.6%#3 | — | — | — |
| TWST | $8.8B#5 | — | 19.7x#12 | 23.3x#2 | 20.3%#4 | 62.8%#1 | -36.2%#1 | -17.4%#7 | -41.4%#2 | — | — | — |
| ORKA | $6.7B#8 | — | 6.0x#6 | — | — | -25.9%#8 | — | -9.5%#4 | — | — | — | — |
| KYMR | $11.0B#3 | — | 6.8x#7 | 279.8x#6 | -16.7%#6 | 39.1%#2 | -891.1%#6 | 19.3%#1 | — | — | 115.2%#3 | — |
| VKTX | $3.4B#13 | — | 5.8x#4 | — | — | -227.1%#15 | — | -61.1%#13 | — | — | -26.0%#5 | — |
| PRAX | $7.9B#7 | — | 5.9x#5 | — | -100.0%#9 | -65.6%#11 | — | -22.6%#9 | — | — | 55.8%#4 | — |
| ERAS | $5.2B#11 | — | 14.3x#10 | — | — | 23.0%#4 | — | -34.4%#10 | — | — | — | — |
| RVMD | $41.9B#2 | — | 16.1x#11 | — | — | -88.5%#13 | — | -43.4%#12 | — | — | 229.1%#2 | — |
| RYTM | $6.1B#9 | — | 69.0x#13 | 32.0x#3 | 45.8%#3 | 24.6%#3 | -101.2%#3 | -0.2%#3 | -127.5%#4 | — | — | — |
| CGON | $5.8B#10 | — | 5.7x#3 | 1439.7x#7 | 254.7%#2 | -82.9%#12 | -4722.1%#7 | -15.6%#6 | -18.8%#1 | — | — | — |
| SLS | $1.8B#14 | — | 12.9x#8 | — | -100.0%#9 | 13.0%#6 | — | -19.5%#8 | — | — | 390.0%#1 | — |
| PCVX | $9.1B#4 | — | 3.3x#1 | — | — | -65.2%#10 | — | -0.0%#2 | — | — | — | — |
| DNTH | $4.7B#12 | — | 4.0x#2 | 2326.4x#8 | -67.3%#8 | -91.1%#14 | -8739.3%#8 | -13.9%#5 | — | — | — | — |
| CYTK | $8.8B#6 | — | — | 99.5x#5 | 376.6%#1 | -33.2%#9 | -695.4%#5 | — | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议